News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche Holding’s Tamiflu Doesn’t Need New Safety Information, Panel Says
December 15, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Dec. 15 (Bloomberg) -- Roche Holding AG's Tamiflu treatment, being stockpiled worldwide for use in a potential avian influenza epidemic, doesn't need extra safety information on its label, a European Union regulatory panel ruled.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Regulatory
MORE ON THIS TOPIC
Regulatory
FDA Mulls National Priority Vouchers for Two Potential Merck Blockbusters: Report
December 18, 2025
·
2 min read
·
Tristan Manalac
Vaccines
CDC Formally Adopts Delayed Hepatitis B Vaccine Dose
December 17, 2025
·
4 min read
·
Tristan Manalac
Autoimmune disease
Nektar Digs Into Mid-Stage Data to Establish Alopecia Efficacy of Rezpeg
December 17, 2025
·
2 min read
·
Tristan Manalac
Podcast
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
December 17, 2025
·
2 min read
·
Heather McKenzie